The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model

Current Eye Research

Volumn 36, Issue 11, 2011, Pages 1005-1013

  Sener, Ender ^a   Yuksel, Nusen ^b   Yildiz, Demir Kursat ^b   Yilmaz, Bulent ^c   Ozdemir, Ozdemir ^d   Caglar, Yusuf ^b   Degirmenci, Esra ^b  

^a Tokat State Hospital   (Turkey)

^b KOCAELI UNIVERSITY   (Turkey)

^c ZIRVE UNIVERSITY   (Turkey)

^d Denizli Military Hospital   (Turkey)

Author keywords

Bevacizumab; Corneal neovascularization; Pegaptanib; Ranibizumab; Trastuzumab

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; POTASSIUM NITRATE; RANIBIZUMAB; SILVER NITRATE; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL BURN; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORNEA THICKNESS; CORNEA VASCULARIZATION; DIGITAL IMAGING; DRUG EFFICACY; ENUCLEATION; FIBROBLAST; HISTOPATHOLOGY; IMAGE ANALYSIS; KERATITIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; CONJUNCTIVA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; EPIDERMAL GROWTH FACTOR; FOLLOW-UP STUDIES; INJECTIONS; MALE; RATS; RATS, WISTAR; RECEPTOR, ERBB-2; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80054696274     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2011.601840     Document Type: Article

References (49)

1. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364. (Pubitemid 26272076)
2. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascu-larization. Curr Opin Ophthalmol 2001;12:242-249.
3. Zhang SX, Ma JX. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res 2007;26:1-37. (Pubitemid 44920203)
4. Beck L Jr, D'Amore PA. Vascular development: cellular and molecular regulation. FASEB J 1997;11:365-373. (Pubitemid 27193941)
5. Ho QT, Kuo CJ. Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol 2007;39:1349-1357. (Pubitemid 47031045)
6. Joussen AM, Poulaki V, Mitsiades N et al. VEGF-dependent conjunctivalization of the corneal surface. Invest Ophthalmol Vis Sci 2003;44:117-123. (Pubitemid 36134263)
7. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in infamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000;41:2514-2522. (Pubitemid 30624378)
8. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in wound-and infammation-related corneal neovasculariza-tion. Invest Ophthalmol Vis Sci 1998;39:18-22. (Pubitemid 28040457)
9. Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 2004;82:557-563. (Pubitemid 39386968)
10. Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in infammation-associ-ated corneal neovascularization. Exp Eye Res 2000;70:419-428. (Pubitemid 30658885)
11. Barros LF, Belfort R Jr. The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. An Acad Bras Cienc 2007;79:389-394. (Pubitemid 47395344)
12. Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2007;245:1577-1579. (Pubitemid 47423342)
13. Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, Vergados IA. Inhibition of cor-neal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 2008;145:424-431.
14. Hurmeric V, Mumcuoglu T, Erdurman C, Kurt B, Dagli O, Durukan AH. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea 2008;27:357-362. (Pubitemid 351440874)
15. Kim R, Toge T. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents. Surg Today 2004;34:293-303. (Pubitemid 38457079)
16. Baker CH, Kedar D, McCarty MF et al. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol 2002;161:929-938. (Pubitemid 34988380)
17. Güler M, Yilmaz T, Ozercan I, Elkiran T. The inhibitory effects of trastuzumab on corneal neovascularization. Am J Ophthalmol 2009;147:703-708.e2.
18. Mahoney JM, Waterbury LD. Drug effects on the neovascu-larization response to silver nitrate cauterization of the rat cornea. Curr Eye Res 1985;4:531-535. (Pubitemid 15066517)
19. Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol 2006;90:1542-1547. (Pubitemid 44862578)
20. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothe-lial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina (Philadelphia, Pa) 2006;26:859-870. (Pubitemid 44547437)
21. Dib E, Rodrigues EB, Maia M et al. [Vital dyes in chromovit-rectomy]. Arq Bras Oftalmol 2009;72:845-850.
22. Lin RC, Rosenfeld PJ. Antiangiogenic therapy in neovascu-lar age-related macular degeneration. Int Ophthalmol Clin 2007;47:117-137. (Pubitemid 46145443)
23. You IC, Kang IS, Lee SH, Yoon KC. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol 2009;87:653-658.
24. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816. (Pubitemid 40051904)
25. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina. 2002;22:143-152.
26. Ishida S, Usui T, Yamashiro K et al. VEGF164-mediated infammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003;198:483-489. (Pubitemid 36976059)
27. Ma DH, Chen JK, Zhang F, Lin KY, Yao JY, Yu JS. Regulation of corneal angiogenesis in limbal stem cell defciency. Prog Retin Eye Res 2006;25:563-590. (Pubitemid 44666509)
28. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309. (Pubitemid 41443415)
29. Spitzer MS, Yoeruek E, Sierra A et al. Comparative antipro-liferative and cytotoxic profle of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol 2007;245:1837-1842. (Pubitemid 350154019)
30. Lu F, Adelman RA. Are intravitreal bevacizumab and ranibi-zumab effective in a rat model of choroidal neovasculariza-tion? Graefes Arch Clin Exp Ophthalmol 2009;247:171-177.
31. Campa C, Harding SP. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr Drug Targets 2011;12:173-181.
32. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284:31-53. (Pubitemid 36331965)
33. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to geftinib and other EGFR-targeting drugs. Clin Cancer Res 2006;12:7242-7251. (Pubitemid 46095395)
34. Guan H, Jia SF, Zhou Z, Stewart J, Kleinerman ES. Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo. Clin Cancer Res 2005;11:2008-2017. (Pubitemid 40471867)
35. Klos KS, Zhou X, Lee S et al. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogen-esis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 2003;98:1377-1385. (Pubitemid 37151491)
36. Nahtaa R, Esteva FC. Herceptin: mechanisms of action and resistance. Cancer Letters. 2006; 232: 123-138
37. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-225.
38. Yen L, You XL, Al Moustafa AE et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000;19:3460-3469. (Pubitemid 30487443)
39. Lane HA, Motoyama AB. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. Ann Oncol. 2001; 12: 21-22
40. Mayfeld S, Vaughn JP, Kute TE. DNA strand breaks and cell cycle perturbation in herceptin treated breast cancer cell lines. Breast Cancer Res Treat 2001;70:123-129. (Pubitemid 33139670)
41. Cooley S, Burns LJ, Repka T, Miller JS. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 1999;27:1533-1541. (Pubitemid 29458428)
42. Mohsin SK, Weiss HL, Gutierrez MC et al. Neoadjuvant tras-tuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005;23:2460-2468. (Pubitemid 47050836)
43. Philip M, Rowley DA, Schreiber H. Infammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004;14:433-439. (Pubitemid 39360991)
44. Edelman JL, Castro MR, Wen Y. Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea. Invest Ophthalmol Vis Sci 1999;40:1112-1123. (Pubitemid 29211448)
45. Bock F, Onderka J, Dietrich T et al. Bevacizumab as a potent inhibitor of infammatory corneal angiogen-esis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007;48:2545-2552. (Pubitemid 351261204)
46. Oh JY, Kim MK, Shin MS, Lee HJ, Lee JH, Wee WR. The anti-infammatory effect of subconjunctival bevacizumab on chemically burned rat corneas. Curr Eye Res 2009;34: 85-91.
47. Cursiefen C, Claus M. Kuchle. Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea 1988;17:611-613
48. Blotnick S, Peopless GE. T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fbroblast growth factor, mitogens for vascular cells and fbroblasts: Differential production and release by CD4+ and CD8+ T cells. Cell Biol 1994;91:2890-2894
49. Dorey CK, Aouididi S. Correlation of vascular permeability factor/vascular endothelial growth factor with extraretinal neovascularization in the rat. Arch Human Ewing's sarcoma cells in vitro and in vivo. Clinical Can Res 2005;11:2008-2017.